← Leaderboards
M Patricia Rivera
University Of North Carolina Chapel Hill
$1,218,276
Attributed
$2,852,355
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $657.5K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,852,355 · 3
By mechanism
R01$2,834,435 · 2
M01$17,920 · 1
Top collaborators
- Louise Henderson6 shared
- Angela M Stover2 shared
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Robert Tarran$14,684,501
- Kim L Brouwer$15,343,248
- Robert S Brown$3,426,728
- David A Savitz$11,328,248
- Scott H Randell$11,007,731
Others in their field
Top investigators on “Recommendation”
- Michelle Vargas · Ppd Development Lp$176,419,297
- Mark R Farfel · Hugo W. Moser Res Inst Kennedy Krieger$119,981,780
- James E Webb · Navy, United States Department Of The$117,850,264
- Kimberly Smith · Ppd Development Lp$115,671,664
- Praduman Jain · Vignet, Inc.$104,076,353
- David M Anderson · University Of Washington$90,543,251
Research focus
RecommendationProceduresMortalityRadiologistFollow-UpPopulation BasedAgedLinkMalignant Neoplasm Of LungLung NoduleAffectData RegistryNeoplasm RegistryNorth CarolinaCancer ControlCancer DetectionGuidelinesCancer EtiologyAdultLow Dose Computed TomographyLungLung Cancer ScreeningCessation Of LifeResearch Support
Grant awards (9)
Lung Cancer Screening: Cumulative Risk and Multilevel Impact of False Positive Findings$643,636
R01 · FY2025 · CA
Lung Cancer Screening: Cumulative Risk and Multilevel Impact of False Positive Findings$657,536
R01 · FY2024 · CA
Comorbidity and Functional Status in a Population Undergoing Lung Cancer Screening$403,840
R01 · FY2023 · CA
Comorbidity and Functional Status in a Population Undergoing Lung Cancer Screening$410,615
R01 · FY2022 · CA
Comorbidity and Functional Status in a Population Undergoing Lung Cancer Screening$390,841
R01 · FY2021 · CA
Comorbidity and Functional Status in a Population Undergoing Lung Cancer Screening$327,967
R01 · FY2020 · CA
FLUORESCENCE BRONCHOSCOPY AND MOLECULAR CHARACTERIZATION OF ABNORMAL LESIONS$3,964
M01 · FY2006 · RR · contact PI
FLUORESCENCE BRONCHOSCOPY AND MOLECULAR CHARACTERIZATION OF ABNORMAL LESIONS$6,597
M01 · FY2005 · RR
Fluorescence Bronchoscopy and Molecular Characterization of Abnormal Lesions$7,359
M01 · FY2004 · RR